Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772787 | 0.74 | NPSR1 (0.55) | MAPTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL13721776 | 0.73 | ALOX15 (0.42) | MAPTTP53MEN1NPC1POLB | |
| SCHEMBL13721907 | 0.73 | ALOX15 (0.42) | MAPTTP53MEN1NPC1POLB | |
| SCHEMBL6771470 | 0.70 | FFAR1 (0.44) | MAPTMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL9418261 | 0.69 | ALOX5 (0.49) | MAPTTP53POLBALDH1A1HSD17B10 | |
| SCHEMBL25295175 | 0.69 | TP53 (0.40) | MAPTTP53POLBALDH1A1HSD17B10 | |
| SCHEMBL25255966 | 0.69 | TP53 (0.40) | MAPTTP53POLBALDH1A1HSD17B10 | |
| SCHEMBL29582293 | 0.68 | TP53 (0.48) | MAPTTP53MEN1KMT2AALDH1A1 | |
| SCHEMBL28290037 | 0.68 | NPSR1 (0.57) | MAPTMEN1NPC1POLBRAB9A | |
| SCHEMBL9392691 | 0.67 | ALOX15 (0.59) | MAPTTP53NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784167-B2 | TREATING OSTEOPOROSIS, OSTEOPENIA, OVARIAN CANCER, BREAST CANCER, ENDOMETRIAL CANCER, ENDOMETRIOSIS, PROSTATE CANCER, ACNE, ANDROGEN-DEPENDENT HAIR LOSS, NON-INSULIN-DEPENDENT DIABETES MELLITUS, OR HYPERCHOLESTEROLEMIA. | BAYER PHARMACEUTICALS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | HSD3B1, HSD3B2, HSD17B1 | MAPT 3975/4885TP53 4064/4885MEN1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.